Development of CNS cell-derived EV markers for the early and differential diagnosis of neurodegenerative diseases - despite recent advances in fluid biomarkers, there remains critical need to identify…
Active Grant Awarded
- Award ID
- R01NS146602
- Recipient
-
Mayo Clinic Jacksonville (A Nonprofit Corporation) UEI GKPBCFV1QMM3
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $597,043
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date 4% complete
- Place of performance
- Jacksonville, FL 32224, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Institute of Neurological Disorders and Stroke awarded Grant R01NS146602 to Mayo Clinic Jacksonville (A Nonprofit Corporation), doing business as Scott Lynch MD, with $597,043 obligated on September 17, 2026. The award is classified as a grant under Assistance Listing 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders, whose stated mission is to seek fundamental knowledge about the brain and nervous system and use it to reduce the burden of neurological disease.
The funded work develops central nervous system cell-derived extracellular vesicle (EV) markers in plasma for early and differential diagnosis of Alzheimer's disease and related dementias, including Lewy body dementia, progressive supranuclear palsy, and corticobasal degeneration. Building on the recipient's prior identification of ATP1A3 as a neuron-specific EV marker, the project extends proteomic profiling and machine learning analysis of ATP1A3-positive brain-derived EVs, which previously yielded 37 disease-specific markers with an area under the curve of 0.86 to 1.00. The proposal also investigates glial EV markers, enriching astrocyte-derived EVs with antibodies against EAAT1 and EAAT2 and oligodendrocyte-derived EVs with antibodies against MOG.
Place of performance is Jacksonville, Florida 32224, and the period of performance runs through August 31, 2031. The source does not identify sub-recipients for this award.
Description
Development of CNS cell-derived EV markers for the early and differential diagnosis of neurodegenerative diseases - despite recent advances in fluid biomarkers, there remains critical need to identify and measure the brain- derived molecules in plasma to accurately differentiate alzheimer's disease (ad) and related dementia (ADRD), including lewy body dementia (LBD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Extracellular vesicles (EVS) are small, cell-derived lipid vesicles that circulate in peripheral biofluids, carrying molecular signatures that reflect their cells of origin. Thus, EV cargo molecules in plasma can be a minimally invasive plasma EV biomarkers to distinguish ad/ADRD. We have recently identified atpase NA+/K+ transporting subunit ALPHA3 (ATP1A3) as a reliable neuron specific EV marker present in brain tissues, cerebrospinal fluids, and plasma samples. Our exciting preliminary proteomic profiling combined with machine learning (ML) analysis of immunoprecipitated ATP1A3+ brain-derived EVS identified 37 disease specific markers, which can differentiate ad and ADRD with high accuracy (area under the curb, ACU 0.86-1.00). Notably, 12 of the candidate proteins were found in the ATP1A3+ plasma EV proteome, while 19 appeared on the SOMASCAN11K array and 12 on the OLINKHT5400 panel, demonstrating the potential for integration with current high-throughput proteomic platforms. In addition, our prior research revealed that glial EV levels increase as alzheimer's disease progresses; thus, this proposal also aims to investigate glial EV markers to enhance diagnostic capabilities. To enrich glial EV subpopulations, we will employ antibodies against excitatory amino acid transporter 1 and 2 (EAAT1/ EAAT2) for astrocyte-derived EVS and myelin oligodendrocyte glycoprotein (MOG) for oligodendrocyte-derived EVS. Our central hypothesis is that neuronal/glial EVS in plasma carry pathological cargo molecules specific to certain disease conditions in the central nervous system, which can serve as biomarkers for neurodegenerative diseases. In this current application, we propose two aims. In aim 1, we will use magnetic bead immunocapture with ATP1A3, EAAT1/2, and MOG antibodies to isolate neuron- and glia-derived EVS from brain and plasma samples of individuals with ad, LBD, PSP, CBD, and controls (N=45 per group). Ultra-sensitive, low-input liquid chromatography-mass spectrometry proteomics will be applied to these enriched EV populations to characterize disease-associated cargo molecules. In aim 2, leveraging the proteomic data from aim 1, we will employ artificial intelligence-driven neural network algorithms to identify EV markers that distinguish ad and related dementias. Selected disease-specific cargo molecules will be incorporated into a plasma EV diagnostic platform using commercially available custom multiplex chip technology. Successful completion of this project will enable the development of blood-based diagnostic assays for ad and related neurodegenerative disorders.
Quick answers
Who received award R01NS146602?
R01NS146602 was awarded to Mayo Clinic Jacksonville (A Nonprofit Corporation) by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 17, 2026.
How much is award R01NS146602 worth?
$597,043 has been obligated on R01NS146602.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award